Switzerland

BMI believes Novartis's Q210 results reinforce our view that emerging markets will drive industry growth. The company delivered a strong performance in H110, posting an 18% increase... 2010-07-15

Core View: The prevalence of chronic diseases will increase dramatically in emerging markets. As economies in these countries develop, incomes rise and people consume more calories,... 2010-06-04

Mid-sized to small specialty pharmaceutical companies are experiencing drastic shortages in funding. The global financial crisis means there is a low appetite for risk and less likelihood... 2010-05-13

BMI Core View: The introduction of government price erosion mechanisms will accelerate across Europe. This view is supported by need for fiscal austerity and the actions of numerous... 2010-05-12

Switzerland-based Actelion, Europe's biggest biotech company, achieved a 20% increase in revenues in 2009, to US$1.65bn from US$1.37bn in 2008, aided by the strong sales of its top-selling... 2010-02-22

US based Cephalon is to acquire Swiss generic drugmaker Mepha AG and its subsidiaries from the family of the late German billionaire Adolf Merckle for US$590mn. The transaction is... 2010-02-04

Swiss drugmaker Roche has posted strong results for 2009, highlighting the opportunities that pandemics such as swine flu can provide to drug companies. The company has reported... 2010-02-03